Sample preparation of circulating cell-free DNA by direct-on-specimen and silica-based methods
Andrew Ford, Charmaine Brown, Chen-Hsiung Yeh*
Circulogene Theranostics, Birmingham, USA
Chen-Hsiung Yeh, PhD
3125 Independence Dr., Suite 301
Birmingham, AL 35209, USA
Abstract: Circulating cell-free DNA (cfDNA) in bloodstream of cancer patients have demonstrated tumor tissue-comparable genetic alterations, offering an unprecedented opportunity for longitudinal and real-time monitoring of highly dynamic tumor heterogeneity. However, the industry is currently using the silica-based cfDNA extraction method which is fundamentally flaw for unavoidable sample loss during binding, washing and elution steps. As a result, clinical cfDNA analysis requires large volume of blood owing to the poor extraction and recovery efficiency. To address these major challenges, we have developed and validated a proprietary direct-on-specimen (DOS) cfDNA enrichment technology. In this report, we set out to evaluate the analytical performance of cfDNA prepared in parallel by our method and the industry standard Qiagen kit.
Read the full report from the IJRDO publication here.